AXSM

Business Context and Reporting Period

Axsome Therapeutics, Inc. (AXSM) is a biopharmaceutical company focused on developing and commercializing innovative medicines for central nervous system (CNS) conditions. This Form 10-Q covers the quarterly period ended March 31, 2026. The company currently commercializes three FDA-approved products: AUVELITY (major depressive disorder and agitation associated with dementia due to Alzheimer's disease), SUNOSI (excessive daytime sleepiness), and SYMBRAVO (acute migraine). The company maintains a deep pipeline of product candidates in various stages of development.

Key Financial Metrics

Note: Total Debt includes $70.0 million in short-term borrowings (revolver) and $117.9 million in long-term loan payable.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased by 57.4% year-over-year, driven by a 58.6% increase in product sales.
  • AUVELITY: Net sales rose to $152.7 million (from $96.2 million).
  • SUNOSI: Net sales rose to $32.6 million (from $24.1 million).
  • SYMBRAVO: Generated $4.1 million in net sales following its June 2025 launch (no sales in Q1 2025).
• Expense Increases:
  • Selling, General and Administrative (SG&A): Increased to $185.0 million (from $120.8 million), primarily due to pre-launch activities for AUVELITY's Alzheimer's indication, expanded sales force, and national direct-to-consumer advertising.
  • Research and Development (R&D): Increased to $52.7 million (from $44.8 million), largely driven by a $10.4 million asset acquisition charge for AXS-20 (balipodect).
• Operating Cash Flow: Net cash used in operating activities improved significantly to $20.7 million (from $43.4 million), reflecting higher revenues and favorable working capital changes.
• Debt Structure: The company maintained a $120.0 million term loan and a $70.0 million revolver under the Blackstone Loan Agreement. The revolver was fully drawn and repaid within the quarter.

Guidance, Outlook, and Risks

• Liquidity: Management believes existing cash resources ($305.1 million) are sufficient to fund anticipated operating requirements for at least twelve months following the filing date.
• Outlook: The company expects expenses to increase through the end of 2026 due to continued commercialization of AUVELITY, SUNOSI, and SYMBRAVO, and the advancement of its pipeline.
• Recent Milestones:
  • April 2026: FDA approved AUVELITY for agitation associated with dementia due to Alzheimer's disease.
  • April 2026: Acquired global rights to AXS-20 (balipodect) from Takeda for $10.4 million.
• Key Risks:
  • Regulatory: Uncertainty regarding FDA approval timelines for pipeline candidates (e.g., AXS-14 received a Refuse to File letter in 2025; FORWARD trial ongoing).
  • Generic Competition: Ongoing Paragraph IV litigation regarding SUNOSI and SYMBRAVO; settlements reached with several generic filers for SUNOSI delaying launch until 2040.
  • Legal: Securities class action litigation was settled and dismissed with prejudice in February 2026; stockholder derivative actions remain pending.
  • Geopolitical/Trade: Potential impact of U.S. tariffs on imported pharmaceuticals and the BIOSECURE Act.

Investor Verification Checklist

• Verify the commercial uptake and reimbursement status of AUVELITY for the new Alzheimer's agitation indication approved in April 2026.
• Monitor the status of the FORWARD Phase 3 trial for AXS-14 (fibromyalgia) following the FDA's Refuse to File letter.
• Review the terms of the Blackstone Loan Agreement, specifically the minimum liquidity covenant of $30.0 million and potential restrictions on dividends or additional debt.
• Assess the impact of the AXS-20 acquisition on the R&D pipeline and future milestone payment obligations to Takeda.
• Track the resolution of pending stockholder derivative actions and any potential financial exposure.
• Confirm the timeline for generic entry of SUNOSI and SYMBRAVO based on ongoing litigation settlements and patent expirations.